Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 5/2019

SECOND TRIMESTER ABORTION: MIFEPRISTONE PLUS MISOPROSTOL vs. MISOPROSTOL PLUS OXYTOCIN

AIDA PETCA 1#, MONA ZVANCA 1#, MIHAELA BOȚ 1, RAZVAN-COSMIN PETCA 2*, CLAUDIA MEHEDINȚU 3, SILVIUS NEGOIȚA 4#, NICOLETA MARU 5

1.Department of Obstetrics and Gynaecology, Elias Emergency Hospital, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2.Department of Urology, “Prof. Dr. Th. Burghele” Clinical Hospital “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3.Department of Obstetrics and Gynaecology, Malaxa Clinical Hospital, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
4.Department of Anaesthesiology and Critical Care, Elias Emergency Hospital, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
5.Department of Anatomy, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Download Full Article PDF

The study compares outcomes from simultaneous administration of Mifepristone and Misoprostol (M&M) with a regimen in which Misoprostol is associated with Oxytocin (M&O) for second-trimester abortion. The primary outcome was uterine evacuation within 12 hours after the first Misoprostol dose, secondary outcomes were adverse effects, post-abortion complications and average cost per patient for each method. 108 patients were enrolled with equal distribution and abortion was complete in both groups. In the M&M group the induction-abortion interval (I-AI) was less than 12 hours in 62.96% (n = 34) compared with the M&O group with 22.22% (n = 12), p < 0.05. Both regimens had high acceptability rates. We did not find any statistical difference in adverse effects observed between the two groups. Administering M&M simultaneously resulted in grater expulsion rates within 12 hours compared with M&O, with the latter regimen demonstrating synergistic benefits, with lower expenses and satisfactory I-AI.